Press Room

    Back

    Press Release - December 19, 2006

    Results of Toronto Hospital Study of Diabetic Mice Supports Sernova Corp's Cellular Therapy Technology


    Kelowna, B.C. -- Sernova Corp. today announced it is encouraged by the results of the study conducted with diabetic mice by Toronto researchers, and subsequently reported by several Canadian news outlets. The results appear to support Sernova's approach to treating diabetes in that Sertoli cells secrete, among other things, "substance P," the neuropeptide Toronto researchers injected into diabetic mice to reverse new onset diabetes. Sernova's approach to treating diabetes is to implant beneath the skin of diabetics, a small device containing insulin producing islets to reverse diabetes, and Sertoli cells to naturally protect the islets from the body's immune system.

    Sernova's chief scientist, Dr. David White was intrigued by the press reports, although he noted that these are preliminary studies and the approach does not address subjects that already have diabetes. He states, "It has been known for several years that Sertoli cells secrete tachykinins such as substance P. The recent news from Toronto would seem to confirm our belief that these secretions are an important component in generating the protective effect of Sertoli cells for islets. Substance P is a pain transmitter and induces vomiting. Therefore we maintain that the best approach is to replace the insulin producing cells that have been destroyed along with protective Sertoli cells, that we know secrete Substance P along with other important growth factors and immunoprotective compounds. We have also known for some time that Sertoli cells can prevent diabetes in the same strain of mice that the Toronto group used."

    Sernova President Justin Leushner said, "The recent press coverage of this study confirms that a cure for diabetes is at the forefront of people's attention and that is why we are moving forward toward commercializing Sertolin our diabetes therapy, which is targeted for human diabetics."

    Sernova's research is focused on compiling pre- clinical data to support an Investigational New Drug application to the United States Food and Drug Administration for their Sertolin Diabetes Therapy. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

    About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

    ON BEHALF OF THE BOARD

    "Justin Leushner"

    Justin Leushner, President

    For further information contact: TEL: (888) 318-7062 FAX: (250) 868-8493 info@sernovacorp.com www.sernovacorp.com

    Phil Morehouse Sernova Corp.

    THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS NEWS RELEASE.

    Back



    Press Releases from:

    2017 2016 2015 2014 2013 2012 2011

    2010 2009 2008 2007 2006 2005 2004

    2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs

    Link

    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance

    PDF

    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario

    Link

    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Publisher: StockInterview.com
    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Publisher: StockInterview.com
    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Publisher: StockInterview.com
    Author: James Finch

    Presentation and Video

    September 11, 2017

    Sernova Fact Sheet

    September 11, 2017

    Sernova's 2017 Corporate Presentation

    PDF Presentation

    Subscribe to Sernova News

Subscribe to our News Dispatch Service

* indicates required




Latest Video and Presentation


Sernova Fact Sheet - / September 11, 2017 Open


Sernova's 2017 Corporate Presentation - PDF Presentation / September 11, 2017 Open

All Presentations →